Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

被引：23
|
作者：
Moskowitz, Alison J. [1 ]
Advani, Ranjana H. [2 ]
Bartlett, Nancy L. [3 ]
Vose, Julie M. [4 ]
Ramchandren, Radhakrishnan [5 ]
Feldman, Tatyana A. [6 ]
LaCasce, Ann S. [7 ]
Christian, Beth A. [8 ]
Ansell, Stephen M. [9 ]
Moskowitz, Craig H. [10 ]
Brown, Lisa [11 ]
Taft, David [11 ]
Ansari, Sahar [11 ]
Zak, Daniel E. [11 ]
Sacchi, Mariana [12 ]
Manley, Thomas [11 ]
Herrera, Alex F. [13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Univ Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] James Canc Hosp, Columbus, OH USA
[9] Mayo Clin, Rochester, MN USA
[10] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[11] Seattle Genet Inc, Bothell, WA USA
[12] Bristol Myers Squibb, Princeton, NJ USA
[13] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122576
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
238
引用
收藏
页数：8
相关论文
共 50 条
  • [1] LONG-TERM FOLLOW-UP RESULTS OF AN ONGOING PIVOTAL STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL)
    Smith, S.
    Chen, R.
    Gopal, A.
    Ansell, S.
    Rosenblatt, J.
    Savage, K.
    Connors, J.
    Engert, A.
    Larsen, E.
    Sievers, E.
    Younes, A.
    HAEMATOLOGICA, 2012, 97 : 456 - 456
  • [2] 2-Year Follow-Up Results From the Phase 1-2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 10 - 11
  • [3] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
  • [4] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2017, 130
  • [5] Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Bartlett, Nancy L.
    Ramchandren, Radhakrishnan
    Vose, Julie M.
    Moskowitz, Alison J.
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Kato, Kazunobu
    Fong, Abraham
    Advani, Ranjana H.
    BLOOD, 2016, 128 (22)
  • [6] Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study
    Wu, Jianqiu
    Song, Yuqin
    Chen, Xinchuan
    Lin, Tongyu
    Cao, Junning
    Liu, Yanyan
    Zhao, Yaozhong
    Jin, Jie
    Huang, Haiwen
    Hu, Jianda
    Luo, Jun
    Zhang, Liling
    Xue, Hongwei
    Zhang, Qingyuan
    Wang, Weiwei
    Chen, Chunxia
    Feng, Jifeng
    Zhu, Jun
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (06) : 984 - 992
  • [7] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Liu, Peng
    Shi, Yuankai
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2012, 120 (21)
  • [9] Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial
    O'Connor, Owen A.
    Lue, Jennifer K.
    Sawas, Ahmed
    Amengual, Jennifer E.
    Deng, Changchun
    Kalac, Matko
    Falchi, Lorenzo
    Marchi, Enrica
    Turenne, Ithamar
    Lichtenstein, Renee
    Rojas, Celeste
    Francescone, Mark
    Schwartz, Lawrence
    Cheng, Bin
    Savage, Kerry J.
    Villa, Diego
    Crump, Michael
    Prica, Anca
    Kukreti, Vishal
    Cremers, Serge
    Connors, Joseph M.
    Kurvuilla, John
    LANCET ONCOLOGY, 2018, 19 (02): : 257 - 266
  • [10] Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
    Advani, Ranjana H.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Brown, Lisa
    Zhang, Chiyu
    Taft, David
    Ansari, Sahar
    Sacchi, Mariana
    Ho, Linda
    Herrera, Alex F.
    BLOOD, 2021, 138 (06) : 427 - 438
12345